| Homocysteine, fibrinogen, and lipoprotein(a) levels are simultaneously reduced in patients with chronic renal failure treated with folic acid, pyridoxine, and cyanocobalamin. | |
| | |
MedLine Citation:
|
PMID: 11229418 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Ischemic heart disease and other complications of atherosclerosis are the usual cause of death in patients with chronic renal failure. Important factors associated with early onset of atherosclerosis in these patients are hyperhomocysteinemia, hyperfibrinogenemia, and elevated levels of lipoprotein(a) (Lp(a)). Folic acid (15 mg/d), pyridoxine (150 mg/d), and cyanocobalamin (1 mg/wk) were administered for 4 weeks in 21 patients receiving dialysis, and a simultaneous, statistically significant reduction in the concentration of homocysteine, fibrinogen, and Lp(a) was found. A positive correlation between decreasing homocysteine and fibrinogen levels was also noted. The parameters studied approached presupplementation values 6 months after vitamins were discontinued. The results suggest that vitamin supplementation has a favorable effect on risk factors of atherosclerosis in patients with renal failure and that interactions may exist between homocysteine, fibrinogen, and Lp(a). |
| | |
Authors:
|
M Naruszewicz; M Klinke; K Dziewanowski; A Staniewicz; H Bukowska |
Related Documents
:
|
21745748 - Relationships between disk displacement, joint effusion, and degenerative changes of th... 22339448 - Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1g>a mut... 22666608 - Clinical and immunopathologic profile of mexican patients with igg4 autoimmune pancreat... 22382608 - Spect study with i-123-ioflupane (datscan) in patients with essential tremor. is there ... 18069918 - Efficacy and safety of intravenous iron therapy as an alternative/adjunct to allogeneic... 8186958 - Motor cortical inhibition and the dopaminergic system. pharmacological changes in the s... |
Publication Detail:
|
Type: Clinical Trial; Journal Article |
Journal Detail:
|
Title: Metabolism: clinical and experimental Volume: 50 ISSN: 0026-0495 ISO Abbreviation: Metab. Clin. Exp. Publication Date: 2001 Feb |
Date Detail:
|
Created Date: 2001-03-02 Completed Date: 2001-03-15 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 0375267 Medline TA: Metabolism Country: United States |
Other Details:
|
Languages: eng Pagination: 131-4 Citation Subset: IM |
Affiliation:
|
Regional Center for Atherosclerosis Research, Pomeranian Academy of Medicine, and the Dialysis Unit of the Provincial Hospital, Szczecin, Poland. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Arteriosclerosis / blood, complications, drug therapy, metabolism Cholesterol / blood Creatinine / blood Drug Therapy, Combination Female Fibrinogen / metabolism* Folic Acid / pharmacology, therapeutic use Homocysteine / blood* Humans Kidney Failure, Chronic / blood, complications, drug therapy*, metabolism Lipoprotein(a) / blood* Male Pyridoxine / pharmacology, therapeutic use Renal Dialysis Risk Factors Triglycerides / blood Urea / blood Uric Acid / blood Vitamin B 12 / pharmacology, therapeutic use Vitamin B Complex / pharmacology*, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Lipoprotein(a); 0/Triglycerides; 12001-76-2/Vitamin B Complex; 454-28-4/Homocysteine; 57-13-6/Urea; 57-88-5/Cholesterol; 59-30-3/Folic Acid; 60-27-5/Creatinine; 65-23-6/Pyridoxine; 68-19-9/Vitamin B 12; 69-93-2/Uric Acid; 9001-32-5/Fibrinogen |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Protein design of an HIV-1 entry inhibitor.
Next Document: Urinary epinephrine and norepinephrine interrelations with obesity, insulin, and the metabolic syndr...